Top Ten Pitfalls to New Medical Device Launches
It is not uncommon for a new medical device to fail to initially live up to projected sales expectations. Early disappointing product sales can produce a hole that a company can spend a long time trying to dig its way out of, having to battle a declining stock price, decreased investor confidence, lower company valuations, and diminished access to capital. The end result may be that both the product and the company are never able to fully recover from the early set-back. Many initial disappointing product roll-outs can be attributed to problems that commonly confront device companies. Product companies have adopted successful strategies to anticipate and overcome many of these issues, and thereby increase the chances of a new product coming strong out-of-the blocks.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Unique Device Identification (UDI) is key to better transparency and traceability in the EU. But this UDI is new to EU medtech manufacturers and complex. The commission has published some helpful pointers.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.